DRKS00031977招募中Unknown
se of Glycomacropeptides (GMP) in 3 – 11 year old children with classical Phenylketonuria in comparison to free amino acid (AAM) supplementation: Effect on metabolic control, micronutrient supply and wellbeing. - GMP in PKU children
niversität Leipzig0 个研究点目标入组 10 人开始时间: 2023年6月12日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 3 Years 至 11 Years（—）
- 性别
- All
入选标准
- •Patients with classical PKU
- •1.Age 3-11 years
- •2.Signed consent (patients and caregivers)
排除标准
- •1. acute illness at start of the study, in particular infections as they might intermittingly deteriorate metabolic control
- •2. every chronic disease or outcome of surgery on the gastrointestinal tract, which influences resorption, metabolism or excretion of food other than PKU.
研究者
相似试验
进行中（未招募）
不适用
GLCYEMIC LEVELS IN CHILDREN OF 6-18 YEARS AGE GROUP USING INHALED CORTICOSTEROIDS FOR ASTHMACTRI/2020/07/026686Dr Anisha Susan Sojan
已完成
不适用
se of Gastrin-Releasing Peptide in Children with Autism DiagnosisChildhood autismF84.0RBR-8cq282Programa de Pós-Graduação em Saúde da Criança e Adolescente - Universidade Federal do Rio Grande do Sul
已完成
不适用
Improvement of the glycolipid metabolism in infants during perisurgical period-1. Influence of preoperative starvatioCleft lip and palateJPRN-UMIN000011644Department of Dental Anesthesiology, Graduate School of Dentistry, Osaka University42
已完成
2 期
A Phase II study of Glypican-3(GPC3) peptide vaccine as adjuvant treatment for Hepatocellular carcinoma(HCC) after Surgical resection or Radiofrequency ablation(RFA)JPRN-UMIN000002614Division of Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East40
已完成
1 期
Phase I clinical study of Glypican-3 peptide vaccine in patients with advanced Hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000001395Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East33